14-day Premium Trial Subscription Try For FreeTry Free

Range Low Price High Price Comment
30 days $21.75 $29.07 Monday, 22nd Apr 2024 ARWR stock ended at $23.92. This is 7.12% more than the trading day before Friday, 19th Apr 2024. During the day the stock fluctuated 9.27% from a day low at $22.24 to a day high of $24.30.
90 days $21.75 $36.72
52 weeks $20.67 $42.48

Historical Arrowhead Research Corporation prices

Date Open High Low Close Volume
Nov 27, 2023 $28.88 $29.14 $28.32 $28.71 863 178
Nov 24, 2023 $28.98 $29.70 $28.77 $29.12 306 089
Nov 22, 2023 $28.88 $29.33 $28.39 $28.96 634 786
Nov 21, 2023 $28.53 $28.75 $28.00 $28.37 690 729
Nov 20, 2023 $28.06 $29.16 $27.86 $28.90 861 539
Nov 17, 2023 $26.29 $28.29 $26.19 $28.06 1 266 600
Nov 16, 2023 $26.57 $27.16 $25.64 $26.06 1 021 746
Nov 15, 2023 $27.46 $29.06 $26.97 $27.01 1 156 931
Nov 14, 2023 $27.35 $27.45 $26.10 $27.40 1 638 457
Nov 13, 2023 $26.57 $26.68 $25.11 $25.97 1 200 358
Nov 10, 2023 $27.03 $27.23 $26.25 $26.96 894 519
Nov 09, 2023 $27.37 $27.37 $26.59 $26.74 895 690
Nov 08, 2023 $27.27 $28.06 $27.02 $27.09 812 012
Nov 07, 2023 $26.90 $27.59 $26.58 $27.51 759 837
Nov 06, 2023 $28.29 $28.30 $26.88 $26.93 1 219 296
Nov 03, 2023 $26.62 $28.27 $26.62 $28.15 1 208 807
Nov 02, 2023 $26.51 $26.67 $25.58 $26.16 794 799
Nov 01, 2023 $25.38 $26.40 $24.67 $25.79 1 279 245
Oct 31, 2023 $23.03 $24.77 $22.87 $24.59 1 354 652
Oct 30, 2023 $23.78 $24.32 $22.95 $23.22 1 148 131
Oct 27, 2023 $24.45 $24.45 $23.58 $23.60 732 841
Oct 26, 2023 $24.09 $24.43 $23.67 $24.40 842 542
Oct 25, 2023 $24.71 $24.75 $23.95 $23.98 798 374
Oct 24, 2023 $24.92 $25.42 $24.79 $25.03 566 357
Oct 23, 2023 $25.20 $25.38 $24.66 $24.69 665 911
Click to get the best stock tips daily for free!

About Arrowhead Research Corporation

Arrowhead Research Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in P... ARWR Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT